Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

NCT00193024 ↗

Phase 2 Terminated 90 enrolled SCRI Development Innovations, LLC Aventis Pharmaceuticals · collab Pharmacia and Upjohn · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.

Timeline

Start: 2001-09
Primary completion: 2003-10
Completion: 2004-10

Publications

Results Hainsworth JD, Yardley DA, Spigel DR, Meluch AA, Rinaldi D, Schnell FM, Greco FA. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. Cancer Invest. 2006 Aug-Sep;24(5):469-73. doi: 10.1080/07357900600814060.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	60 mg/m2	Intravenous
Subject	Epirubicin	Small molecule	90 mg/m2	Intravenous

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

Summary

Timeline

Publications

Drugs

Indications